Voxcan at the forefront of COVID-19 research

Test platform for in-vitro and in-vivo efficacy assessments against COVID-19

Recognized as an expert in infectious disease biology and pathogenesis, Voxcan is currently working on multiple SARS-CoV-2 virus in-vitro and in-vivo studies. Our scientists are experienced in animal model efficacy testing and our BSL3 facilities are tailored to manage airborne viruses. We are approved to acquire and work with clinically relevant BSL3 isolates including coronavirus (SARS-CoV-2).

Since the COVID19 pandemic, Voxcan has built a mature SARS-CoV-2 program in order to support the pharmaceutical and biotechnology industries. We can assist you in preclinical drug development of your antivirals or vaccines using vero-E6 based in-vitro platform and in-vivo transgenic h-ACE2 mouse model as well as Syrian Golden hamster model.

Our internal capacities enable us to explore both of infection and inflammatory phases and provide you with the following readouts: 

  • Antiviral plaque assay counting (PFU)
  • RT-qPCR for the detection of the virus and of your compounds
  • Histopathological analysis
  • Biomarker quantification including cytokines

Voxcan can contribute to the success of your research projects by elaborating a customized study design.

Please feel free to contact us for more details.